LEXINGTON, Mass.--(BUSINESS WIRE)--SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the publication of their latest preclinical ...
A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, ...
Investigators presented initial results from the phase 3 RAMPART trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma.
Women (n = 288) undergoing adjuvant therapy for early-stage breast cancer were recruited from two outpatient clinics. Women completed a baseline assessment before adjuvant therapy and a post-treatment ...
Please provide your email address to receive an email when new articles are posted on . Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among ...
Innovators reveal how next-generation adjuvants and biologicals are reshaping sustainable crop protection in Episode 1 of Adjuvants Uncovered.
Industry leaders unpack global regulatory hurdles — and emerging opportunities — shaping the future of adjuvant innovation in Episode 2 of "Adjuvants Uncovered".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback